Background: It is unknown whether balloon angioplasty can be a first choice treatment for intracranial atherosclerosis related emergent large vessel occlusion (ICASELVO) with small clot burden. The microcatheter first pass effect is a valid predictor of ICAS-ELVO with small clot. Objective: To determine balloon angioplasty efficacy as first choice treatment for ICASELVO involving the microcatheter first pass effect during endovascular treatment (EVT). Methods: This continuous retrospective analysis assessed ICASELVO patients presenting with the microcatheter first pass effect during EVT. Patients were divided into two first choice treatment based groups: preferred balloon angioplasty (PBA) and preferred mechanical thrombectomy (PMT). Efficacy and safety outcomes were compared between groups. Results: Seventy six patients with ICAS-ELVO involving the microcatheter first pass effect during EVT were enrolled. Compared with patients in PMT group, patients in PBA group were associated with (i) a higher rate of first pass recanalization (54.0% vs. 28.9%, p=.010) and complete reperfusion (expanded thrombolysis in cerebral ischemia;2c; 76.0% vs. 53.8%, p=.049), (ii) a shorter puncture to recanalization time (49.5 min vs. 56.0 min, p<.001), (iii) less operation costs (48,499.5 vs. 99,086.0, p<.001),and (iv) more excellent functional outcomes (modified Rankin scale:0-1; 44.0% vs. 19.2%, p=.032) at 90 days. No significant differences in symptomatic intracranial hemorrhage (12.0% vs. 15.4%, p>.999) and mortality (10.0% vs. 7.7%, p>.999) were noted. Logistic regression analysis revealed that first choice treatment was an independent predictor of 90 day excellent functional outcomes (adjusted odds ratio [aOR] =0.10, 95% CI: 0.02~0.66, p=.017). Conclusion: Balloon angioplasty, as the first choice treatment, potentially improves 90 day functional outcomes for ICASELVO patients with microcatheter first-pass effect during EVT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.